Piper Sandler analyst Allison Bratzel lowered the firm’s price target on Humacyte (HUMA) to $1 from $3 and keeps a Neutral rating on the shares following Q4 earnings. The company reported more progress on VAC approvals, with the new, lower $17k price helping accelerate hospital orders by aligning more closely with comparable surgical products, but it’s unclear to the firm how soon this will translate to significant demand.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HUMA:
- Humacyte: Near-Term Commercial Headwinds but Platform Catalysts Support Long-Term Upside and Buy Rating
- Morning Movers: AstraZeneca jumps following tozorakimab trial results
- Humacyte reports Q4 EPS (13c), consensus (14c)
- Options Volatility and Implied Earnings Moves Today, March 27, 2026
- HUMA Upcoming Earnings Report: What to Expect?